ReviewMaterials today. Bio2026
Glucose oxidase-powered nanocatalytic medicine: Rewiring tumor metabolism for multimodal cancer therapy.
Review in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Immobilization of glucose oxidase and catalase on magnetite nanoparticles as functional catalyst supports.Journal of materials chemistry. C · 2026Article
- Advances in artificial metabzymes for macrophage polarization in tumor metabolic immunotherapy.Materials today. Bio · 2026Article
- Nanomaterials in osteoarthritis therapy: advances in drug delivery, tissue regeneration, and implant engineering.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer cells exhibit metabolic reprograming characterized by a preference for aerobic glycolysis (the Warburg effect), which supports their rapid proliferation while promoting immune invasion and microenvironment remodeling. Glucose oxidase (GOX) has emerged as a powerful therapeutic agent that exploits this metabolic vulnerability through targeted glucose depletion. Recent advances in nanocarrier technology have addressed critical limitations of native GOX, including systemic toxicity, short circulation half-life, immunogenicity, and instability in physiological environments. Engineered GOX nanoconstructs demonstrate remarkable tumor-specific cytotoxicity through dual mechanisms: (1) starvation via glucose deprivation and (2) oxidative damage through reactive oxygen species generation. Importantly, GOX-mediated modulation of tumor microenvironment parameters - acidity, H
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.